CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: Comparison with aromatic/hydrophobic adduct formation

Carcinogenesis

Volumn 23, Issue 12, 2002, Pages 1969-1977

  Alexandrov, Kroum ^a   Cascorbi, Ingolf ^b   Rojas, Margarita ^a   Bouvier, Guy ^c   Kriek, Erik ^d   Bartsch, Helmut ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c NONE   (France)

^d NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC COMPOUND; BENZO[A]PYRENE; BIOLOGICAL MARKER; CYTOCHROME P450 1A1; DIHYDROXYBENZO[A]PYRENE OXIDE; DNA; GLUTATHIONE TRANSFERASE; PROTEIN P53;

CARCINOGEN DNA INTERACTION; CIGARETTE SMOKING; CODON; DNA ADDUCT; ENZYME ACTIVITY; GENE MUTATION; GENOTYPE; HOMOZYGOSITY; HUMAN; HYDROPHOBICITY; HYPOTHESIS; LUNG CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; REVIEW; TUMOR SUPPRESSOR GENE;

BENZO(A)PYRENE; CARCINOGENS; CYTOCHROME P-450 CYP1A1; DNA ADDUCTS; FEMALE; GENES, P53; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; LUNG; MALE; MUTATION; SMOKING;

EID: 0036955117     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/23.12.1969     Document Type: Review

References (75)

1. Kriek,E., Rojas,M., Alexandrov,K. and Bartsch,H. (1998) Polycyclic aromatic hydrocarbon-DNA adducts in humans: relevance as biomarkers for exposure and cancer risk. Mutat. Res., 400, 215-231.
2. Osborn,M.R. and Crosby,N.T. (1987) Benzopyrenes. In Cambridge Monographs on Cancer Research. Cambridge University Press, Cambridge, pp. 1-323.
3. Wynder,E.L. and Graham,E.A. (1950) Tobacco smoking as a possible etiologic factor in bronchogenic carcinoma. J. Am. Med. Assoc., 143, 329-336.
4. Kreyberg,L. (1954) The significance of histological typing in the epidemiology of the primary epithelial lung tumours: a study of 446 cases. Br. J. Cancer, 8, 199-208.
5. Denissenko,M.F., Pao,A., Rang,M. and Pfeifer,G.P. (1996) Preferential formation of benzo(a)pyrene adducts at lung cancer mutational hotspots in P53. Science, 274, 430-432.
6. Smith,L.E., Denissenko,M., Bennett,W.P., Li,H., Amin,S., Tang,M. and Pfeifer,G.P. (2000) Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J. Natl Cancer Inst., 92, 803-810.
7. Hollstein,M. Sidransky,D., Vogelstein,B. and Harris,C.C. (1991) p53 mutations in human cancers. Science, 253, 49-53.
8. Hussain,S.P. and Harris,C.C. (1998) Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumour suppressor genes. Cancer Res., 58, 4023-4037.
9. Gelboin,H. (1980) Benzo(a)pyrene metabolism, activation and carcinogenesis: role of regulation of mixed-function oxidases and related enzymes. Physiol. Rev., 60, 1107-1165.
10. Park,J.-Y.K., Shigenaga,M.K. and Arnes,B.N. (1996) Induction of cytochrome P4501A1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin or indol (3,2-b)carbazole is associated with oxidative DNA damage. Proc. Natl Acad. Sci. USA, 93, 2322-2327.
11. Kellerman,G., Luyten-Kellermman,M. and Shaw,C.R. (1973) Genetic variation of aryl hydrocarbon hydroxylase in human lymphocytes. Am. J. Hum. Genet., 25, 327-331.
12. Kouri,R.E., McKinney,C.E., Slomiany,D.J., Snodgrass,D.R., Wray,N.P. and McLemore,T.L. (1982) Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res., 45, 5030-5037.
13. Karki,N.T., Pokela,R., Nuutinen,L. and Pelkonen,O. (1987) Aryl hydrocarbon hydroxylase in lymphocytes and lung tissue from lung cancer patients and controls. Int. J. Cancer, 39, 565-570.
14. McLemore,T.L., Adelberg,S., Liu,M.C., McMahon,N.A., Yu,S.J. and Hubbard,W.C. (1990) Expression of CYP1A1gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J. Natl Cancer Inst., 82, 1333-1339.
15. Petruzzelli,S., Camus,A.M., Carrozzi,L., et al. (1988) Long-lasting effects of tobacco-smoking on pulmonary drug-metabolizing enzymes: a case-control study on lung cancer patients. Cancer Res., 48, 4695-4700.
16. Anttila,S., Hietanen,E., Vainio,H., Camus,A.M. Gelboin,H.V., Park,S.S., Heikkilae,L., Karjalainen,A. and Bartsch,H. (1991) Smoking and peripheral type of cancer are related to high levels of pulmonary cytochrome P450IA in lung cancer patients. Int. J. Cancer, 47, 681-685.
17. Anttila,S., Vainio,H., Hietanen,E., et al. (1992) Immunohistochemical detection of pulmonary cytochrome P450IA and metabolic activities associated with P450IA1 and P450IA2 isozymes in lung cancer patients. Environ. Health Perspect., 98, 179-182.
18. Cohen,G.M., Mehta,R. and Brown,M. (1979) Large interindividual variations in metabolism of benzo(a)pyrene by peripheral lung tissue from lung cancer patients. Int. J. Cancer, 24, 129-133.
19. Prough,R.A., Sipal,Z. and Jakobsson,S.W. (1977) Metabolism of benzo(a)pyrene by human lung microsomal fractions. Life Sci., 21, 1629-1636.
20. Rojas,M., Camus,A.M., Alexandrov,K., Husgafvel-Pursianen,K., Antilla,S., Vainio,H. and Bartsch,H. (1992) Stereoselective metabolism of (-)-benzo[a]pyrene-7,8-diol by human lung microsomes and peripheral blood lymphocytes: effect of smoking. Carcinogenesis, 13, 929-933.
21. Harris,C., Autrup,H., Connor,R., Barrett,L.A., McDowell,E.M. and Trump,B.F. (1976) Interindividual variation in binding of benzo(a)pyrene to DNA in cultured human bronchi. Science, 194, 1067-1069
22. Bartsch,H., Castegnaro,M., Rojas,M., Camus,A.M., Alexandrov,K. and Lang,M. (1992) Expression of pulmonary cytochrome P4501A1 and carcinogen-DNA adduct formation in high risk subjects for tobacco-related lung cancer. Toxicol. Lett., 64, 477-483.
23. Bartsch,H., Petruzzelli,S., De Flora,S., et al. (1992) Carcinogen metabolism in human lung tissues and the effect of tobacco smoking: results from a case-control multicenter study on lung cancer patients. Environ. Health Perspect., 98, 119-124.
24. Kawajiri,K., Nakachi,K., Imai,K., Yoshii,A., Shinoda,N. and Watanabe,J. (1990) Identification of genetically high risk individuals to lung cancer by DNA polymorphism of the cytochrome P4501A1 gene. FEBS Lett., 263, 131-133.
25. Petersen,D.D., McKinney,C.E., Ikeya,K., Smith,H.H., Bale,A.E. and McBride,O.W. (1991) Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am. J. Hum. Genet., 48, 720-725.
26. Cosma,G., Crofts,F., Currie,D., Wirgin,L., Toniolo,P. and Garte,S.J. (1993) Racial differences in restriction fragment length polymorphisms and messenger RNA inducibility of human CYP1A1 gene. Cancer Epidemiol. Biomarkers Prev., 2, 53-57.
27. Cosma,G., Crofts,R, Currie,D., Toniolo,P. and Garte,S.J. (1993) Relationship between genotype and function of the human CYP1A1 gene. J. Toxicol. Environ. Health, 40, 309-316.
28. Crofts,F., Taioli,E., Tranchman,J., Cosma,G.N., Currie,D., Toniolo,P. and Garte,S.J. (1994) Functional significance of different human CYP1A1 genotypes. Carcinogenesis, 15, 2961-2963.
29. Kiyohara,C., Nakanishi,Y., Inutsuka,S., Takayama,K., Hara,N., Motohiro,A., Tanaka,K., Kono,S. and Hirohata,T. (1998) The relationship between CYP1A1 aryl hydrocarbon hydroxylase activity and lung cancer in a Japanese population. Pharmacogenetics, 8, 315-323.
30. Jacquet,M., Lambert,V., Baudoux,E., Muller,M., Kremers,P. and Gielen,J. (1996) Correlation between P450CYP1A1 inducibility, MspI genotype and lung cancer incidence. Eur. J. Cancer, 32A, 1701-1706.
31. Stucker,I., Jacquet,M., Waziers,I., Cénée,S., Beaune,P., Kremers,P. and Hémon,D. (2000) Relation between inducibility of CYP1A1,GSTM1 and lung cancer in a French population. Pharmacogenetics, 10, 617-662.
32. Wedlund,P.J., Kimura,S., Gonzales,F.J. and Nebert,D.W. (1994) 1462V mutation in the human CYP1A1 gene: lack of correlation with either the MspI kb (M2) allele or CYP1A1 inducibility in a three-generation family of East-Mediterranean descent. Pharmacogenetics, 4, 24-26.
33. Vaury,C., Laine,R., Noguiez,P., Coppet,P., Jaulin,C., Praz,F., Pompon,D. and Amor-Gueret,M. (1995) Human glutathione S-transferase M1 null genotype is associated with high inducibility of cytochrome P4501A1 gene transcription. Cancer Res., 55, 5520-5523.
34. Smart,J. and Daly,A.K. (2000) Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics, 10, 11-24.
35. Smith,G.B.J., Harper,P.A., Wong,J.M.Y., Lam,M.S.M., Reid,K.R., Petsikas,D. and Massey,T.E. (2001) Human lung microsomal cytochrome P4501A1 (CYP1A1) activities: impact of smoking status and CYP1A1, arylhydrocarbon receptor and glutathione S-transferase M1 genetic polymorphisms. Cancer Epidemiol. Biomarkers Prev., 10, 839-853.
36. Cauchi,S., Stücker,I., Solas,C., et al. (2001) Polymorphisms of human aryl hydrocarbon receptor (AhR) gene in a French population: relationship with CYP1A1 inducibility and lung cancer. Carcinogenesis, 22, 1819-1824.
37. Anttila,S., Lei,X-D., Elovaara,E., Karjalainen,A., Sun,W., Vainio,H. and Hankinson,O. (2000) An uncommon phenotype of poor inducibility of CYP1A1 in human lung is not ascribed to polymorphisms in the AHR, ARHT, or CYP1A1 genes. Pharmacogenetics, 10, 741-751.
38. 462: assessment of a role for the rare allele in carcinogenesis. Cancer Res., 56, 3926-3933.
39. Persson,I., Johansson,I. and Ingelman-Sundberg,M. (1997) In-vitro kinetics of two human CYP1A! variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem. Biophys. Res. Commun., 231, 227-230.
40. Schwarz,D., Kisselev,P., Cascorbi,I., Schunck,W.H. and Roots,I. (2001) Differential metabolism of benzo(a)pyrene and benzo(a)pyrene-7,8-diol by human CYP1A1 variants. Carcinogenesis, 22, 453-459.
41. Mannervik,B. and Danielson,H. (1988) Glutathione S-transferases - structure a nd catalytic activity. CRC Crit. Rev. Biochem. 23, 283-337.
42. Hayes,J.D. and Strange,R.C. (2000) Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology, 61, 154-166.
43. Sundberg,K., Johansson,A.-F., Stenberg,G., Widersten,M., Seidel,A., Mannervik,B. and Jernstrom,B. (1998) Differences in the catalytic efficiencies of allelic variants of glutathione S-transferase P1-1 towards carcinogenic diol-epoxides of polycyclic aromatic hydrocarbons. Carcinogenesis, 19, 433-436.
44. Sundberg,K., Dreij,K., Seidel,A. and Jernström,B. (2002) Glutathione conjugation and DNA adduct formation of dibenzo(a,1)pyrene and benzo(a)pyrene diol-epoxides in V79 cells stably expressing different human glutathione transferases. Chem. Res. Toxicol., 15, 170-179.
45. Bartsch,H., Nair,U., Risch,A., Rojas,M., Wikman,H. and Alexandrov,K. (2000) Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol. Biomarkers Prev., 9, 3-28.
46. Autrup,H. (2000) Genetic polymorphisms in human xenobiotic-metabolizing enzymes as susceptibility factors in toxic response. Mutat. Res., 464, 65-76.
47. Cuzick,J., Routledge,M.N., Jenkins,D. and Gamer,R.C. (1990) DNA adducts in different tissues of smokers and non-smokers. Int. J. Cancer, 45, 673-678.
48. Phillips,D.H., Schoket,B., Hewer,A., Bailey,E., Kostic,S. and Vincze,I. (1990) Influence of cigarette smoking on the levels of DNA adducts in human bronchial epithelium and white blood cells. Int. J. Cancer, 46, 569-575.
49. Dunn,B.P., Vedal,S., San,R.H.C., Kwan,W.-F., Nelems,B., Enarson,D.A. and Stich,H.F. (1991) DNA adducts in bronchial biopsies. Int. J. Cancer, 48, 485-492.
50. Van Schooten,F.J., Hillebrand,M.J.X., van Leeuwen,F.E., Lutgerink,J.T., van Zandwijk,N., Jansen,H.M. and Kriek,E. (1990) Polycyclic aromatic hydrocarbon-DNA adducts in lung tissue from lung cancer patients. 11, 1677-1681.
51. Bartsch,H. and Hietanen,E. (1996) The role of individual susceptibility in cancer burden to environmental exposure. Environ. Health Perspect., 104, 569-577.
52. Ryberg,D., Skaug,V., Hewer,A., et al. (1997) Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis, 18, 1285-1289.
53. Schoket,B., Phillips,D.H., Poirier,M.C., Kostic,S. and Vincze,I. (1998) Smoking-associated bulky DNA adducts in bronchial tissue related to CYP1A1 and GSTM1 genotypes in lung patients. Carcinogenesis, 19, 841-846.
54. Schoket,B., Papp,G., Lévay,K., Mrackova,G., Kadlubar,F.F. and Vincze,I. (2001) Impact of metabolic genotypes on levels of biomarkers of genotoxic exposure. Mutat. Res., 482, 57-69.
55. Butkiewicz,D., Cole,K.L., Phillips,D.H., Harris,C.C. and Chorazy,M. (1999) GSTM1, GSTP1, CYP1A1 and CYP2D6 polymorphism in lung cancer patients from an environmentally polluted region of Poland: correlation with lung DNA adduct levels. Eur. J. Cancer Prev., 8, 315-323.
56. Cheng,Y.-W., Chen,C.Y., Lin,P., Chen,C.-P., Huang,K.H., Lin,T.-S., Wu,M.-H. and Lee,H. (2000) DNA adduct level, in lung tissue may act as a risk biomarker of lung cancer. Eur. J. Cancer, 36, 1381-1388.
57. Shields,P.G., Bowman,E.D., Harrington,A.M., Doan,V.T. and Weston,A. (1993) Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res., 53, 3486-3492.
58. Kato,S., Bowman,E.D., Harrington,A.M., Blomeke,B. and Shields,P. (1995) Human lung carcinogen-DNA adducts levels mediated by genetic polymorphisms in vivo. J. Natl Cancer Inst., 87, 902-907.
59. Bartsch,H. (1996) DNA adducts in human carcinogenesis: Etiological relevance and structure-activity relationship. Mutat. Res., 340, 67-79.
60. Rojas,M., Alexandrov,K., Cascorbi,I., et al. (1998) High benzo(a)pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1MspI/MspI-GSTM1*0/*0 genotypes. Pharmacogenetics, 8, 109-118.
61. 32p-postlabelling analysis of PAH-DNA adducts in human lung and relationship to TP53 mutations. Mutat. Res., 368, 275-282.
62. Alexandrov,K., Rojas,M., Geneste,O., Castegnaro,M., Camus,A.-M., Petruzzelli,S., Giuntini,C. and Bartsch,H. (1992) An improved fluorometric assay for dosimetry of benzo[a]pyrene diol-epoxide-DNA adducts in smokers lung: comparison with total bulky adducts and aryl hydrocarbon hydroxylase activity. Cancer Res., 52, 6248-6253.
63. 32P-postlabelling and ELISA. Carcinogenesis, 15, 557-560.
64. Rojas,M., Cascorbi,I., Alexandrov,K., Kriek,E., Auburtin,G., Mayer,L., Koop-Schneider,A., Roots,I. and Bartsch,H. (2000) Modulation of benzo(a)pyrene diol-epoxide-DNA adduct levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism. Carcinogenesis, 21, 35-41.
65. Lodovici,M., Akpan,V., Giovannini,L., Migliani,F. and Dolara,P. (1998) Benzo[alpyrene diol-epoxide DNA adducts and levels of polycyclic aromatic hydrocarbons in autoptic samples from human lungs. Chem.-Biol. Interact., 116, 199-212.
66. Sticha,R.K., Staretz,E., Wang,M., Liang,H., Kenney,M.J. and Hecht,S.S. (2000) Effects of benzyl isothiocyanate and phenethyl isothiocyanate on benzo[a]pyrene metabolism and DNA adduct formation in the A/J mouse. Carcinogenesis, 21, 1711-1719.
67. Schwerdtle,T., Seidel,A. and Hartwig,A. (2002) Effect of soluble and particulate nickel compounds on the formation and repair of stable benzo[a]pyrene DNA adducts in human lung cells. Carcinogenesis, 23, 47-53.
68. Anttila,S., Hirvonen,A., Vainio,H., Husgafvel-Pursiainen,K., Hayes,J.D. and Ketterer,B. (1993) Immunohistochemical localisation of glutathione S-transferases in human lung. Cancer Res., 53, 5643-5648.
69. Coles,B., Yang,M., Lang,N.P. and Kadlubar,F.F. (2000) Expression of hGSTP1 alleles in human lung and catalytic activity of the native protein variants towards 1-chloro-2,4-dinitrobenzene, 4-vinylpyridine and (+)-anti benzo[a]pyrene-7,8-diol-9,10-oxide. Cancer Lett., 156, 167-175.
70. Wall,K.L., Gao,W.S., te Koppele,J.M., Kwei,G.Y., Kaufman,F.C. and Thurman,R.G. (1991) The liver plays a central role in the mechanism of chemical carcinogenesis due to polycyclic aromatic hydrocarbons. Carcinogenesis, 12, 783-786.
71. Geneste,O., Camus,A.-M., Castegnaro,M., Petruzelli,S., Macchiarini,P., Angeletti,C.A.A. and Bartsch,H. (1991) Comparison of pulmonary DNA adduct levels, measured by 32P-postlabelling and aryl hydrocarbon hydroxylase activity in lung parenchyma of smokers and ex-smokers. Carcinogenesis, 12, 1301-1305.
72. Mollerup,S., Ryberg,D., Hewer,A., Phillips,D.H. and Haugen,A. (1999) Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res., 59, 3317-3320.
73. Ozava,S., Schoket,B., McDaniel,L.P., Tang,Y.-M., Ambrasone,C.B, Kostic,S., Vincze,I. and Kadlubar,F.F. (1999) Analyses of bronchial bulky DNA adduct levels and CYP2C9,GSTP1 and NQO1 genotypes in a Hungarian study population with pulmonary diseases. Carcinogenesis, 20, 991-995.
74. Hou,S.-M., Fält,S., Yang,K., Nyberg,F., Pershagen,G., Hemminki,K. and Lambert,B. (2001) Differential interactions between GSTM1 and NAT2 genotypes on aromatic DNA adduct level and HPRT mutant frequency in lung cancer patients and population controls. Cancer Epidemiol. Biomarkers Prev., 10, 133-140.
75. Hussain,S.P., Amstad,P., Raja,K., et al. (2001) Mutability of p53 hotspot codons to benzo(a)pyrene diol-epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung. Cancer Res., 61, 6350-6355.